Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) Income from Continuing Operations (2020 - 2025)

HCW Biologics (HCWB) has disclosed Income from Continuing Operations for 6 consecutive years, with 3440513.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 11.96% year-over-year to 3440513.0, compared with a TTM value of 12736295.0 through Sep 2025, up 66.0%, and an annual FY2024 reading of 30110804.0, down 15.81% over the prior year.
  • Income from Continuing Operations was 3440513.0 for Q3 2025 at HCW Biologics, up from 3671475.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1880810.0 in Q1 2022 and bottomed at 15295676.0 in Q2 2024.
  • Average Income from Continuing Operations over 5 years is 4947737.63, with a median of 3907903.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations plummeted 232.08% in 2024, then surged 76.0% in 2025.
  • Year by year, Income from Continuing Operations stood at 3112505.0 in 2021, then plummeted by 85.11% to 5761713.0 in 2022, then plummeted by 86.87% to 10766768.0 in 2023, then surged by 68.4% to 3402683.0 in 2024, then decreased by 1.11% to 3440513.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for HCWB at 3440513.0 in Q3 2025, 3671475.0 in Q2 2025, and 2221624.0 in Q1 2025.